Exchange: NASDAQ·Updated 07:30 PM EST

About KLRS

About

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
20

Frequently Asked Questions

Advertisement|Remove ads.